| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/09/2001 | WO2001057022A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001057008A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | WO2001057006A1 Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer |
| 08/09/2001 | WO2001057002A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | WO2001056993A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001056987A1 Tosylproline analogs as thymidylate synthase inhibitors |
| 08/09/2001 | WO2001056981A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | WO2001056902A1 Inverted aerosol dispenser |
| 08/09/2001 | WO2001056607A1 Integrin expression inhibitors |
| 08/09/2001 | WO2001056603A1 Cd40-binding apc-activating molecules |
| 08/09/2001 | WO2001056601A2 Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| 08/09/2001 | WO2001056599A2 Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors |
| 08/09/2001 | WO2001056598A2 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
| 08/09/2001 | WO2001056590A2 Utilization of protein kinase inhibitor alpha |
| 08/09/2001 | WO2001056589A2 Physiologically active compositions of basidiomycotina and araliaceae extracts |
| 08/09/2001 | WO2001056575A1 Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid |
| 08/09/2001 | WO2001056566A1 Neovascularization inhibitory compositions and method of inhibiting neovascularization |
| 08/09/2001 | WO2001056565A1 C-4 carbonate taxanes |
| 08/09/2001 | WO2001056564A1 C10 heterosubstituted acetate taxanes as antitumor agents |
| 08/09/2001 | WO2001056563A1 Adamantyl derivatives as anti-cancer agents |
| 08/09/2001 | WO2001056560A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | WO2001056552A2 Farnesyl protein transferase inhibitors for treating breast cancer |
| 08/09/2001 | WO2001056548A2 Liposomes composition produced by a dehydration-rehydration process |
| 08/09/2001 | WO2001056547A2 Preparation of aqueous clear solution dosage forms with bile acids |
| 08/09/2001 | WO2001056387A1 Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen |
| 08/09/2001 | WO2001021796A3 Gl50 molecules and uses therefor |
| 08/09/2001 | WO2001019966A3 Isolation of muscle-derived stem cells and uses therefor |
| 08/09/2001 | WO2001019814A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 08/09/2001 | WO2001016312A3 Nucleic acid based modulators of gene expression |
| 08/09/2001 | WO2001007066A3 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2001002017A3 Erythropoietin conjugates with polyethylenglycol |
| 08/09/2001 | WO2000076487A3 Use of paclitaxel and steriod derivatives as aromatase inhibitors for the treatment of cancer |
| 08/09/2001 | WO2000075144A8 Peroxynitrite decomposition catalysts and methods of use thereof |
| 08/09/2001 | WO2000074729A3 Alpha or beta emitters to fragments in radioimmunotherapy |
| 08/09/2001 | WO2000074646A3 Novel liposomal vector complexes and their use in gene therapy |
| 08/09/2001 | WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation |
| 08/09/2001 | WO2000070046A9 Secreted polypeptides and corresponding polynucleotides |
| 08/09/2001 | WO2000066095A3 Use of estrone derivatives as antitumour agents |
| 08/09/2001 | WO2000066094A3 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents |
| 08/09/2001 | WO2000063351A3 Carbohydrate-modifying enzymes |
| 08/09/2001 | WO2000062813A3 Cationic peg-lipids and methods of use |
| 08/09/2001 | WO2000059878A3 INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF |
| 08/09/2001 | WO2000037643A3 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 08/09/2001 | US20010012889 36 human secreted proteins |
| 08/09/2001 | US20010012885 Conjugate consisting of an active substance and a non-exogeneous native protein |
| 08/09/2001 | US20010012858 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 08/09/2001 | US20010012854 Administering to the patient a diamide compound to induce apoptosis in tumor cells |
| 08/09/2001 | US20010012845 Adminstering an E-type prostaglandin ligand and a cyclooxygenase-2 enzyme selective inhibitor compound in combination with a carrier to treat inflammation |
| 08/09/2001 | US20010012844 Quinazoline, nitrothiazole and indolinone based hydrophobic formulations for oral administration for treating cell proliferation disorder in a mammal |
| 08/09/2001 | US20010012837 Anti-ulcer composition |
| 08/09/2001 | US20010012836 Determining the presence or absence of a mutation in the nucleotide sequence or absence of a mutation in nucleotide sequence encoding the specific polypeptides in the genome of the subject and analyzing for presence of polypeptide |
| 08/09/2001 | US20010012621 Determining the expression of lysyl oxidase, the expression of lysyl oxidase indicating that the compound is capable of suppressing ras functions |
| 08/09/2001 | US20010012523 Plant extracts for the treatment of increased bone resorption |
| 08/09/2001 | US20010012517 Anticancer agent |
| 08/09/2001 | US20010012515 Isolated polypeptide |
| 08/09/2001 | DE10003653A1 Vektorkonstrukte zur gentherapeutisch vermittelten Radioiodtherapie entdifferenzierter und medullärer Schilddrüsen-Karzinome sowie nicht-thyreoidaler Tumore und ihrer Metastasen Vector constructs for gene therapy mediated radioiodine therapy of medullary thyroid carcinoma and dedifferentiated and non-thyroidal tumors and their metastases |
| 08/09/2001 | CA2399982A1 G-protein coupled receptors |
| 08/09/2001 | CA2399792A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399644A1 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 08/09/2001 | CA2399603A1 Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| 08/09/2001 | CA2399274A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 08/09/2001 | CA2399214A1 Novel heterocyclic amide derivatives |
| 08/09/2001 | CA2399124A1 Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid |
| 08/09/2001 | CA2399116A1 C-4 carbonate taxanes |
| 08/09/2001 | CA2399083A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | CA2399058A1 Targeting peptides |
| 08/09/2001 | CA2399026A1 Mucin-1 derived antigens and their use in immunotherapy |
| 08/09/2001 | CA2399022A1 Ligand for vascular endothelial growth factor receptor |
| 08/09/2001 | CA2398998A1 Cd40-binding apc-activating molecules |
| 08/09/2001 | CA2398996A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | CA2398915A1 Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors |
| 08/09/2001 | CA2398889A1 Antisense modulation of survivin expression |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2398752A1 Tosylproline analogs as thymidylate synthase inhibitors |
| 08/09/2001 | CA2398678A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr |
| 08/09/2001 | CA2398674A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | CA2398255A1 Bcl-2-like polynucleotides, polypeptides, and antibodies |
| 08/09/2001 | CA2398215A1 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2396774A1 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 08/09/2001 | CA2369079A1 Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | CA2369050A1 Methods for preventing or attenuating pathoangiogenic conditions |
| 08/09/2001 | CA2368541A1 C10 carbamoyloxy substituted taxanes as antitumor agents |
| 08/09/2001 | CA2368540A1 C7 carbonate substituted taxanes as antitumor agents |
| 08/09/2001 | CA2368534A1 C7 heterosubstituted acetate taxanes as antitumor agents |
| 08/09/2001 | CA2368510A1 C7 carbamoyloxy substituted taxanes as antitumor agents |
| 08/09/2001 | CA2368502A1 C10 heterosubstituted acetate taxanes as antitumor agents |
| 08/09/2001 | CA2368151A1 C10 carbonate substituted taxanes as antitumor agents |
| 08/09/2001 | CA2367661A1 Taxane formulations having improved solubility |
| 08/08/2001 | EP1122318A2 Diagnostic method for the detection of polymorphisms related to the human urokinase plasminogen activator receptor |
| 08/08/2001 | EP1122261A2 13 and 14-membered antibacterial macrolides |
| 08/08/2001 | EP1122243A1 Novel imidazoles with anti-inflammatory activity |
| 08/08/2001 | EP1121598A1 Detection of pleiotrophin |
| 08/08/2001 | EP1121444A2 Protein kinase homologs |
| 08/08/2001 | EP1121442A2 Recombinant e1a deleted adenoviral vectors |
| 08/08/2001 | EP1121441A2 Selectively replicating viral vectors |
| 08/08/2001 | EP1121439A2 Methods and compositions for inhibiting neoplastic cell growth |